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Abstract: Squamous cell carcinoma of the oral region (OSCC) is one of the most common 
and highly aggressive malignancies worldwide, despite the fact that significant results have 
been achieved during the last decades in its detection, prevention and treatment. Although 
many efforts have been made to define the molecular signatures that identify the clinical 
outcome of oral cancers, OSCC still lacks reliable prognostic molecular markers. Scientific 
evidence indicates that transition from normal epithelium to pre-malignancy, and finally to 
oral carcinoma, depends on the accumulation of genetic and epigenetic alterations in a 
multistep process. Unlike genetic alterations, epigenetic changes are heritable and 
potentially reversible. The most common examples of such changes are DNA methylation, 
histone modification, and small non-coding RNAs. Although several epigenetic changes 
have been currently linked to OSCC initiation and progression, they have been only 
partially characterized. Over the last decade, it has been demonstrated that especially 
aberrant DNA methylation plays a critical role in oral cancer. The major goal of the present 
paper is to review the recent literature about the epigenetic modifications contribution in 
early and later phases of OSCC malignant transformation; in particular we point out the 
current evidence of epigenetic marks as novel markers for early diagnosis and prognosis as 
well as potential therapeutic targets in oral cancer. 
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1. Introduction 
Head and neck cancers constitute the sixth most common malignant tumors worldwide, affecting 
approximately 650,000 people and causing almost 350,000 cancer deaths per year [1,2]. These 
malignancies encompass tumors arising from the epithelium of the nasal and oral cavity, paranasal 
sinus, pharynx and larynx. Oral cancer is the most frequent cancer of the head and neck district, with 
squamous cell carcinoma being by far the commonest single entity, accounting alone for about 90% of 
all malignancies of the oral cavity [3]. Due to its related high mortality and low cure rate, oral 
squamous cell carcinoma (OSCC) represents a major public health problem, with a great individual 
and socioeconomic impact. In fact, despite of the many advancements made in the field of oral cancer 
prevention and multimodality treatments, the five-year survival rate for OSCC remains at a 
disappointingly stable level, almost unchanged over the past 20 years [4,5]. The poor prognosis of 
OSCC is mainly due to a low response rate to current therapeutic strategies, particularly for tumors 
diagnosed in advanced stage. This specific subset of patients is characterized by a high occurrence of 
invasion to surrounding tissues, lymph node and distant metastasis and by a peculiarly high risk of 
second malignancy during the patient’s lifetime.   
Oral carcinogenesis is a multistep process modulated by endogenous and environmental factors. 
Among these latter, a major role is played by tobacco and alcohol regular intake [6], as well as by 
Human Papillomavirus (HPV) persistent infection [7–11]. These predisposing factors may lead to a 
wide range of genetic and epigenetic events that promote genomic instability and tumor development 
and progression. The genetic alterations involved in the development and progression of oral 
premalignancy and OSCC, are caused by irreversible changes in DNA sequence including gene 
deletions, amplifications and mutations leading both to oncogenes activation or tumor suppressor 
genes inactivation [12,13]. 
Epigenetics is another major player in multistep carcinogenesis of oral cancers. Here we discuss the 
current literature in the field of the epigenetics of oral cancer, placing a great deal of emphasis on 
DNA methylation, histone modification and post-transcriptional gene down-regulation by microRNAs. 
The emerging but still debated role of high-risk HPV persistent infections in determining a different 
subset of OSCC will also be discussed, reviewing some of recent publications about this topic and 
pointing out the relationship between HPV infection and cancer prone epigenetic modifications. We 
finally aim to highlight the important translational implications of the epigenetic regulation as new 
diagnostic, prognostic and predictive markers in oral cancer, an actually growing field of research due 
to the poor reliability of conventional markers in OSCC diagnosis, treatment and follow-up [12]. 
2. Epigenetics 
The epigenetic changes refer to any heritable modifications in gene expression without alterations 
of the DNA sequence; they occur more frequently than gene mutations and may persist for the entire 
cell life and even for multiple generations [14]. The transcription of each gene may change from  Int. J. Mol. Sci. 2012, 13                 
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high-level expression to complete silencing, depending on the influence of the “epimutations” which 
interfere with the action of activators and suppressors on specific promoters in the chromatin 
context [15]. With minor exceptions (T- and B-cells of the immune system), all differentiation processes 
are triggered and maintained through epigenetic mechanisms. Epigenetic inheritance includes DNA 
methylation, histone modifications and RNA-mediated silencing. Disruption of any of these three 
distinct and mutually reinforcing epigenetic mechanisms leads to inappropriate gene expression, 
resulting in cancer development and other “epigenetic diseases” [16–19] (Table 1). 
Table 1. The most common epigenetic alterations. 
Epigenetic change  Putative mechanism Biological  consequence 
DNA hypomethylation  Activation of cellular oncogenes 
Activation of transposable element 
Increased proliferation, growth advantage 
Genomic instability, transcriptional noise 
DNA hypermethylation  De novo hypermethylation of CpG islands 
within gene promoters leading to silencing of 
tumor suppressors and cancer-associated genes 
Genomic and chromosomal instability, 
increased proliferation, growth advantage 
Loss of imprinting (LOI)  Reactivation of silent alleles, biallelic expression 
of imprinted genes 
Expansion of precursor cell population 
Relaxation of X-
chromosome inactivation 
Mechanisms is unknown but it appears to be 
age-related 
Altered gene dosage, growth advantage 
Histone acetylation  Gain-of-function 
Loss-of-function 
Activation of tumor promoting genes 
Defects in DNA repair and checkpoints 
Histone deacetylation  Silencing of tumor suppressor genes  Genomic instability, increased proliferation 
Histone methylation  Loss of heritable patterns of gene expression 
(“cellular memory”) 
Genomic instability, growth advantage 
MicroRNAs (miRNAs) 
amplification in cancer 
Function as oncogenes  Neoplastic transformation 
MicroRNAs (miRNAs) 
deletion in cancer 
Function as tumor suppressors.  Neoplastic transformation 
3. DNA Methylation 
DNA methylation is the most common and the best-studied epigenetic modification [20]. It is 
mediated by different DNA methyltransferases (DNMT) [21] and usually involves lysine and arginine 
residues on histone tails. The methylation of DNA refers to the covalent addition of a methyl group  
to the 5-carbon (C5) position of cytosine bases that are located 5' to a guanosine base in a CpG 
dinucleotide. CpG dinucleotides, scattered throughout the genome, are usually found clustered in  
0.5–4 kb regions, named CpG islands, the major part of which localized at the promoter of tumor 
suppressor genes [22]. CpG islands of growth-regulatory genes promoter regions are often found 
hypermethylated in tumors, this event causing the transcriptional “silencing” of tumor suppressor 
genes [23,24], contributing to cancer progression; on the contrary, it has also been described the 
derepression of proto-oncogenes transcription by hypo/demethylation, this leading to increased 
mutation rates and to chromosome instability, which constitutes an early hallmark of tumor  
cells [25–27].  Moreover, the loss of function of tumor-suppressor genes, which often occurs in  
tumors, has been ascribed more frequently to epigenetic silencing through methylation than to genetic Int. J. Mol. Sci. 2012, 13                 
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defects [20,28], supporting the hypothesis that epigenetic alterations have a significant role in every 
step of carcinogenesis. The genes most frequently hypermethylated and silenced in cancer cells reside 
in chromosome regions commonly showing loss of heterozygosity. The LOH of hypermethylated 
genes may provide a selective growth advantage to tumor cells, and is often involved in metastatic 
ability and in tumor neo-angiogenesis [29]. 
4. DNA Methylation in Oral Carcinogenesis 
Although a clear correlation between the epigenetic-driven deregulation of gene expression and the 
oral cancer progression is at present not fully demonstrated, hypermethylation and consequent silencing 
of several tumor suppressor genes, out of a group of more than 40 genes, has been identified in  
OSCC [20] (Table 2); the genes found hypermethylated in OSCC cover a wide range of cellular 
processes, including cell cycle control (p16, p15), apoptosis (p14, DAPK, p73 and RASSF1A), Wnt 
signalling (APC, WIF1, RUNX3), cell-cell adhesion (E-cadherin), and DNA-repair (MGMT and 
hMLH1) [30–33]. 
Table 2. The most common genes silenced from promoter methylation. 
Gene Locus  Function  Alterations  Ref 
ABO  9q34 Blood  group  antigen Hypermethilation  34 
APC  5q21 Signal  transduction  Hypermethilation  33,35 
ATM  11q22-q23 Tumor  suppressor  Hypermethilation  4,30,36,37 
C/EBPα  19q13 Tumor  suppressor  Hypermethilation  38 
CDKN2A  9p21 Cell  cycle  LOH,  hypermethilation  4,39 
CRABP2  1q21 Nuclear  transcriptional 
regulator 
Hypermethilation 40 
DAPK  9q Apoptosis  Hypermethilation  4,30,32,34,35,37 
DCC  18q21 Tumor  suppressor  Hypermethilation  4,30,34,37 
DKK3  11p Transcriptional  regulator  Hypermethilation 12 
E-cadherin  16q22 Signal  transduction  Hypermethilation  4,32,41,42,34,36 
EDNRB  13q22 Signal  transduction  Hypermethilation  39 
GSTP1  11q13 Detoxification  of  carcinogens Hypermethilation  30,43 
H3K4  1q21.2 Histone  Hypermethilation  44 
HIN1  12p13 Tumor  suppressor  Hypermethilation  45 
Hmlh1   3p21 DNA  repair  Hypermethilation  30,32,34–36 
LHX6  9q33 Transcriptional  regulator  Hypermethilation  38 
MGMT  10q26 DNA  repair  Hypermethilation  4,30,32,41,35,37 
MINT family  / /  Hypermethilation  30 
miR137  1p21.3 Tumor  suppressor  Hypermethilation  46 
miR193a  17q11.2 Tumor  suppressor  Hypermethilation  46 
MX1  21q22 /  Hypermethilation  40 
p14  9p21 Apoptosis  LOH,  hypermethilation  30,34 
p15  9p21  Cell cycle  LOH, deletion, mutation, 
hypermethilation 
4,37 
p16  9p21  Cell cycle  LOH, mutation, deletion, 
hypermethilation 
30,32,35–38 Int. J. Mol. Sci. 2012, 13                 
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Table 2. Cont. 
p53  17p13  Tumor suppressor  Mutation, hypermethilation  30 
p73  1p36 Apoptosis  Hypermethilation  30,34,35,38 
PTEN  10q23 Tumor  suppressor  Hypermethilation  47–50 
RARB2  17q21 Nuclear  transcriptional 
Regulator 
Hypermethilation 4,30,42,34,35,37 
RASSF-1  3p21 Apoptosis  Hypermethilation  4,32,51,37 
Rb  13q14  Tumor suppressor  Hypermethilation, mutation  35 
RUNX3  1p36 Transcriptional  regulator  Hypermethilation  32,39 
SFRP1  8p11.21 Transcriptional  regulator  Hypometilation  52 
SFRP1-2-4-5  8p11.21 
4q31.3 
7p14.1 
10q24.1 
Transcriptional regulator  Hypermethilation  52,38,53 
TCF21  6q23-q24 epithelial-mesenchymal 
interactions 
Hypermethilation 38 
THBS1  15q15  cell-to-cell and cell-to-matrix 
interactions 
Hypermethilation 35 
TIMP3  22q12 epithelial-mesenchymal 
interactions 
Hypermethilation 4,37 
WIF1  12q14 Transcriptional  regulator  Hypermethilation  32,52 
σ-14-3-3  1p36 Signal  transduction  Hypermethilation  30,34 
4.1. CDKN2A 
The methylation rate of CDKN2A has been widely investigated and reported in the literature. 
CDKN2A gene maps on chromosome 9p21 and encodes the cell cycle regulatory protein p16, which 
inhibits the cyclin-dependent kinase 4 and 6 activity, inducing cell-cycle arrest in the G1 phase.  
The reported incidence of hypermethylation of p16 ranges from 23% to 76% in OSCC [41,43,54–58]. 
Some studies examined also this phenomenon in oral mucosa with different degree of dysplasia  
(pre-neoplastic lesions, OIN) [59,60] and in normal adjacent mucosa, showing higher values of 
hypermethylation in OIN compared to normal mucosa, but lower than in the OSCC. 
4.2. E-Cadherin and N-Cadherin 
CDH1 gene (cadherin 1 type 1) is located on chromosome 16q22.1 and encodes for E-cadherin, a 
120-kd single-span transmembrane glycoprotein, with five extracellular and one cytoplasmic domain, 
interacting with catenins. This molecule is mainly involved in the formation of adhesive junctions in 
epithelial cells, playing a fundamental role in in many aspects of the establishment and maintenance  
of intercellular adhesion, cell polarity, intracellular signaling and tissue architecture. Several studies 
evaluating E-cadherin expression in different carcinomas, documented the crucial role of this molecule 
during tumor progression and invasion. In fact E-cadherin absence is strictly linked to alterations in 
cell key functions and motility. In addition it is shown that the loss of its expression is frequently 
involved in tissue metastasis. Similarly to others malignancies, it was shown a correlation between low 
expression of E-cadherin and a more aggressive behaviour of OSCC. Hypermethylation of CDH1 was Int. J. Mol. Sci. 2012, 13                 
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also extensively reported [41,57,61–63]: in these studies the E-cadherin gene hypermethylation 
frequency ranged between 7% and 46% [30,64–65]. In a recent review, Vered et al. analyzed the 
recent literature evaluating the immunoexpression of E-cadherin in OSCC, highlighting the confusion 
existing about the expression of this protein in normal and neoplastic tissue. They stressed the need for 
a critical review of the IHC-based expression evaluation of this molecule, in order to better define the 
association between its expression and clinical outcome [66]. 
In a recent study, Di Domenico M examined N-cadherin expression, a calcium-dependent adhesion 
protein, in series of 94 OSCC. Neoplastic tissue showed a significantly higher expression of this protein, 
almost exclusively cytoplasmic, than normal tissue. In addition tumors with high N-cadherin value were 
characterized by a more aggressive behaviour. These data suggested that N-cadherin could have a 
potential role in predicting the biological behavior of SCC [67]. 
4.3. PTEN 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor-suppressor gene 
located on chromosome 10q23.3, the loss of which expression is thought to be involved in important 
cellular processes including survival, differentiation, proliferation, apoptosis and invasion. In addition, 
due to lack of control of the signaling pathways that mediate apoptosis and migration, such as 
Ras/phosphoinositide 3-kinase (PI3K)/AKT, it plays a fundamental role in tumor cell survival and 
proliferation and metastasis. PTEN is frequently deficient in several malignancies because of 
mutations or epigenetic changes [68,69] In addition evidences has also been provided supporting that 
CpG islands of the PTEN promoter are methylated in several type of human cancers, such as 
endometrial carcinoma [70], gastric [71], non-small-cell lung carcinoma [72] and cervical cancer [73]. 
Kurasawa et al. analyzed the immunohistochemical expression of PTEN in 113 OSCC and 9 OSCC 
cell-lines [47]. The resulting data showed a significant difference of expression between tumor 
samples and normal tissues. No mutations were showed, but in 4 out 6 OSCC cell lines a lower 
expression of PTEN mRNA were observed. Taken together these results supported the hypothesis that 
PTEN plays an important role in OSCC pathogenesis and that its down-regulation is due to 
hypermethylation [47]. However, the role of PTEN in OSCC remains uncertain. Squarize et al. 
demonstrated that aggressive OSCC did not express PTEN [48] and Shin et al. showed that the genetic 
or epigenetic inactivation of PTEN was related to OSCC carcinogenesis [49], while several authors 
didn’t support this association [50,74,75]. Several studies have investigated the role of pTEN in OSCC 
and correlated the abnormal expression of PTEN to the occurrence, development and invasion of 
OSCC [76]. In a recent review, Diez-Perez et al. report the data relative to a comparison study between 
oral cancer tissue and normal mucosa, showing a 77.8% reduction of gene expression, due to its 
promoter methylation [42]. 
4.4. P53 
TP53 gene maps on chromosome 17p13.1 and encode a tumor suppressor protein, also called p53, 
involves in many fundamental cell processes, such as cell cycle progression, cellular differentiation, 
DNA-repair and apoptosis. When an endogenous or exogenous stress occurs, p53 levels increase and 
lead to block cell cycle, allowing the DNA-repair. Loss of p53 function alters the ability of cells to Int. J. Mol. Sci. 2012, 13                 
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respond to stress or damage, leading to genomic instability. P53 is mutated in the majority of human 
cancers, including oral cancers, with frequency ranging from 25% to 69% [77–80]. In several instances, 
however, p53 shows a loss of function due to epigenetic events, instead of genetic alterations. This is 
the case of the epigenetic inactivation of p53 non mutated protein by the E6 protein of high-risk HPVs 
(mostly HPV16 and 18), in OSCC as in some laryngeal cancers (see below for further discussion about 
this topic). 
4.5. DAPK1 
DAPK1 (death associated protein kinase 1) gene maps on chromosome 9q34.1, it encodes a  
pro-apoptotic calcium/calmodulin regulated serine/threonine kinase inducing apoptosis (p53-dependent 
apoptotic checkpoint) [43,58,81]. The reported frequency of DAPK promoter hypermethylation ranges 
from 18% to 27% [64,82,83]. 
4.6. MGMT 
MGMT gene is located on chromosome 10q26, it encodes MGMT (06-methylguanine-DNA methyl 
transferase), a DNA repair enzyme that removes adducts caused by alkylating agents; such DNA repair 
activity favors the resistance of cells to treatment-induced apoptosis. Silencing this gene allows alkylated 
guanine to accumulate, restoring apoptosis [43,58]. The frequency of hypermethylation in OSCC ranges 
from 7% to 68% [41,43,58,65,82–85]. 
4.7. RARB2 
RARB2 (retinoic acid receptor B2 gene) is a tumor suppressor gene belonging to the RARB family, 
mapping on chromosome 3p24. It is frequently inactivated in cancer, mainly by methylation. It is 
linked with the deregulation of cell proliferation in tumors as well as in preneoplastic lesions. Promoter 
methylation of the RARB2 gene was generally reported in around 55% of lung SCLC, in 19% of 
urothelial carcinoma, in 27.5% of breast carcinomas, in prostate cancers, in endometrial carcinomas, 
colorectal carcinomas and it has been significantly associated with aggressive tumor phenotypes and 
patients survival in salivary glands carcinomas. RARB2 promoter methylation has been observed  
also in cancers of the head and neck region (67%) and in a significant percentage of precancerous 
lesions of the same district (>50%) [86]. Very interestingly, recent reports indicate that RARB2 
methylation is independent from tumor site or stage, but is related to the higher age of patients 
(probably as an expression of the long time of action of carcinogens on the mucosal epithelium) and to 
the aggressiveness of tumors and poor prognosis of patients [45]. 
4.8. RASSF1 and RASSF2 
RASSF1 (3p21.3) and RASSF2 (20p13) belong to the Ras association family (RASSF) of proteins 
involved in the Ras/PI3K/AKT pathways. Huang et al. showed that in almost the 50% of patients treated 
with radiotherapy Ras/PI3K/AKT pathways were activated in association with RASSF1A/RASSF2A 
gene silencing through promoter methylation [51]. In addition, Imai T et al. found RASSF2 methylated 
in 26% of OSCC evaluated [87]. Int. J. Mol. Sci. 2012, 13                 
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Hypermethylation of p14ARK, p16
INK4a, p15, MGMT, DAPK, GSTP1, RARB and p53 have been 
found in dysplasia and in histologically normal appearing margin of OSCC resection. Several studies 
suggest that methylation could be considered as an early promising marker of malignant progression. 
However, other studies have failed to correlate the hypermethylated state with progression toward 
cancer of OINs or to recurrence of OSCC in the site of excision. Therefore, this aspect deserves further 
investigation on a greater series of cases [12,43,58,59]. 
Less is known on the presence and role of hypomethylation: to date, it has been reported only the 
possible occurrence of SFRP1 (secreted frizzled-related protein 1) (8p11.21) hypometylation in OSCC, 
but the data are too few to achieve an overview of the phenomenon in these tumors. Contrary to 
Sogabe et al. who observed that SFRP1 together with SFRP2 and SFRP5 were methylated in OSCC, 
Pannone et al. found SFRP1 significantly demethylated in cancer (p < 0.05) [52]. 
5. miRNA 
MicroRNAs (miRNAs) are a recently discovered class of non-coding endogenous small 
RNAs [88,89] which have a crucial role in the control of gene expression and are associated with 
promotion and progression of malignancies [90]. They are involved in many fundamental cellular 
processes such as proliferation, development, differentiation and apopotosis in normal and neoplastic 
cells, where they are referred to as oncomiRs (oncogenic miRNA). They act as mediators of epigenetic 
gene regulation, by interacting with mRNA, either by inhibiting mRNA translation or causing mRNA 
degradation [91]. Recent studies have been shown that miRNAs act as putative tumor suppressors and 
may also undergo epigenetic silencing in cancer [92,93]. Although there are still few studies focusing 
on the miRNA involvement in oral carcinogenesis, the interest about their functional roles in OSCC is 
rapidly growing. Cervigne et al. examined microRNA (miR) expression changes in 43 sequential 
progressive oral leukoplakia samples from 12 patients and 4 non-progressive leukoplakias from  
4 different patients [94]. The findings were validated using quantitative RT-PCR in an independent 
cohort of 52 progressive dysplasias and oral squamous cell carcinomas (OSCCs), and 5 non-progressive 
dysplasias [94]. Global miR expression profiles distinguished progressive leukoplakia/OSCC from  
non-progressive leukoplakias/normal tissues. Of 109 miRs, which were highly expressed exclusively in 
progressive leukoplakia and invasive OSCC, miR21, miR181b, and miR345 expression was consistently 
increased and associated with increases in lesion severity during progression. The authors hypothesized 
that overexpression of miR21, miR181b, and miR345 may play an important role in malignant 
transformation [94]. Wong TS found that the level of miR-133a and miR-133B was significantly 
decreased in OSCC when compared with normal epithelia samples. These low levels led to the 
activation of a potential oncogene piruvate kinase type M2 [95]. Kozaki et al. investigated the  
miR-137 and miR-193a expression levels alteration in some OSCC cell lines, demonstrating that the 
epigenetic silencing of both miRNA, caused by DNA hypermethylation, could have a key function  
in oral cancer progression [46]. miR-17-92 was shown to play pleiotropic functions during both 
normal development and malignant transformation; it was demonstrated that the expression levels of  
mir-17-92 polycistronic cluster increased in cultured carcinoma cell lines in comparison to normal 
human keratinocytes [96,97]. Hu et al. demonstrated that miR-504 plays an important role during 
carcinogenesis, acting as a negative regulator of p53. In fact overexpression of miR-504 causes low Int. J. Mol. Sci. 2012, 13                 
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demonstrated that miR-504 plays an important role during levels of the tumor suppressor [98]. The 
potential role of miR-504 as new diagnostic, prognostic and therapeutic tools has been recently 
discussed by Wu et al. and by Gorennchtein et al., both hypothesizing a clinic advantage in OSCC 
patient management [99,100]. Table 3 summarizes several miRNAs whose expression is deregulated 
in OSCC. The accumulating data about this topic let envisage mi-RNAs as one of the most valuable 
biomarkers and therapeutic targets in current OSCC research. During recent years, the trend of 
research in mi-RNA and OSCC field has evolved from solely searching altered specific miRNAs to 
exploring molecular networks and connections between miRNAs and signaling pathways involved in 
the progression of OSCC. 
Table 3. Deregulated miRNA in squamous cell carcinoma of the oral region (OSCC). 
Cellular function  microRNAs  Expression in OSCC 
Proliferation and 
apoptosis 
miR-137, miR-193a, miR-133a, miR-133b, 
miR-503, miR-15a 
Down-regulated 
miR-21, miR-24 and miR-184  Up-regulated 
Metastasis 
miR-222 and miR-138  Down-regulated 
miR-211 and miR-31  Up-regulated 
Chemoresistance 
miR-21  Down-regulated 
miR-23a, miR-214, miR-98  Up-regulated 
6. Chromatin Dynamics and Histones Modifications 
The chromatin structure is highly regulated by complex interactions between many molecular 
pathways, that influence normal and tumor cell fate, for that concerning DNA replication, transcription, 
and repair, cell growth and differentiation, apoptosis and every crucial cell functions. Histones and 
chromatin modifiers mainly induce changes of chromatin architecture. Histones have a structural role 
in the chromatin architecture entering into the constitution of nucleosomes. Acetylation, methylation, 
phosphorylation and ubiquitination are major histone modifications, combination of which may 
constitute the “histone code” that extends and modulates the genetic code [101,102]. Among 
molecules that regulate the chromatin assembly, histone chaperones play an essential role. They drive 
histones incorporation into newly synthesized or remodeled chromatin [103]. In this process, the 
Chromatin Assembly Factor-1 (CAF-1) exerts a pivotal role: it destabilizes heterochromatic structures 
during replication, allowing the replication machinery to progress through heterochromatin. CAF-1 is a 
protein complex, formed of three subunits with different molecular weight (p48, p60 and p150) and 
delivers histones H3 and H4 on newly synthesized DNA [104] during DNA replication and DNA 
repair. CAF-1 facilitates the incorporation and assembly into chromatin of H3K56 acetylated histones, 
in response to oxidative stress [105] and DNA damage [106–108]; moreover it contributes to resolve 
the mismatch-containing strands, restoring chromatin structure on the completion of double strand 
break repair [109]. In particular, the p48 subunit works as partner for the retinoblastoma protein 
RbAp48, participating in cell-growth suppression, and is involved in histone metabolism [110]; the 
p150 and p60 subunits are essential for the S-phase progression [111,112] and for the restoration of the 
original chromatin organization following DNA repair [113]. Moreover, p150 protein directly interacts 
with the proliferating cell nuclear antigen (PCNA) and is actively involved in proliferation-linked I
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Several lines of evidence implicated histone acetylation in human malignancies. The histone 
acetylation status mainly depends on the activity of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). Some recent works evaluated the role of histone deacetylase (HDAC) 
inhibitors in OSCC cell lines and OSCC tissues [120–127]. HDAC inhibitors are a new group of  
anti-neoplastic drugs that promote acetylation of core histones, leading in turn to the uncoiling of 
chromatin and activation of several genes involved in the regulation mechanisms of cell survival, 
proliferation, differentiation, and apoptosis. Sakuma et al. found a higher expression of deacetylase  
6 in OSCC cell lines and OSCC tissue samples in comparison to normal oral tissue and nine OSCC 
cell lines [120]. Moreover, Sato et al. highlighted the importance of timing of addition of HDAC 
inhibitors when used in combination with cisplatin, in a study performed on OSCC cell lines. In fact, 
CDDP-treated cells displayed varying degrees of apoptotic responses depending on timing of HDAC 
inhibitors addition [121]. Rihiishi et al. observed a cooperative effect between histone deacetylase 
(HDAC) inhibitor (suberoylanilide hydroxamic acid) on cisplatin (CDDP)-induced apoptosis on 
human OSCC cell lines [122]. Chang et al. evaluated the expression of Histone deacetylase 2 protein 
on 20 cases of oral epithelial dysplasia and 93 cases of OSCC [123]. In consideration of the resulting 
data showing that overexpression of the HDAC protein is a frequent event in OSCC, they suggested 
that Histone deacetylase 2 protein could be used as a prognostic factor in oral SCC. Based on reports 
supporting the useful association between HDAC inhibitors and some traditional chemotherapeutic 
agents, Shen and colleagues evaluated the potential combinative effect of low dose cisplatin 
andsuberoylanilide hydroxamic acid, in OSCC cell lines [125]. The authors concluded that concurrent 
treatment with SAHA enhanced tumor cell sensitivity to subtoxic doses of cisplatin. 
7. Human Papilloma Virus (HPV) 
High Risk Papillomavirus (HR-HPV) persistent infection has been recently indicated as an 
independent risk factor for head and neck cancers and, although it is still a “hot” debated topic, a 
growing body of literature has documented the link between high risk papillomavirus (HR-HPV) 
persistent infection of oral epithelium and the development of OSCC [7,8,128–132]. Miller and 
Johnstone, the first to publish a meta-analysis on HPV prevalence in precancer lesions, cancer and 
normal oral mucosa, showed that HPV was 2–3 times more likely to be detected in oral precancer 
lesions, and 4.7 times more likely to be present in oral carcinomas, when compared with normal 
mucosa [133]. Syrjänen reviewed the HPV literature published prior to 1998, and the pooled HPV 
detection rates in normal oral mucosa, OL and OSCC ranged from 13% to 33% depending on the 
technique used to detect HPV (PCR, ISH or both) [134]. 
In a recent meta-analysis study, Syrjänen et al. showed that HPV significantly increases the risk for 
OSCC, as compared with the controls (OR 3.98, 95% CI: 2.62–6.02); nevertheless, in the total lack of 
prospective cohort studies, the authors were unable to take a position on the temporal relationship 
between HPV infection and oral malignancies [135]. The results of this meta-analysis showed a strong 
association between HPV and OSCC in accordance with previous studies [131–138]. 
The association between high risk papillomavirus (HR-HPV) persistent infection of oral epithelium 
and the development of OSCC characterizes a distinct subgroup of malignancy arisen in a younger and 
higher socio-economic group, often non-smokers/non-drinkers [139]. This subset of HR-HPV positive Int. J. Mol. Sci. 2012, 13                 
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lesions shows different genetic and molecular profile and has been associated with a more favorable 
prognosis, compared to the HPV-negative ones, although more often they are poorly differentiated. In 
fact, HR-HPV-associated OSCCs are characterized by a significantly lower malignant progression rate 
and by a better responsiveness to chemo-and radiotherapy when compared with tumors of the same 
grade and stage, negative for viral infection [140,141]. However, it is not yet well known if the better 
biological behavior and the better response to the adjuvant therapies of the HR-HPV-associated OSCC 
might be due to the indirect action of innate or acquired cofactors, moreover to formally confirm the 
role of HPV as an etiological agent of OSCC, additional evidence is required. 
From the molecular point of view, HR-HPV+ tumors are characterized by high genomic instability, 
due to a dysregulation of cell cycle control, epigenetically induced by the E6 and E7 HR-HPV 
oncoproteins [142]. E6 and E7 proteins bind and degrade, respectively, p53 and the retinoblastoma 
(pRb) proteins, leading to the continuous expression of the cyclin-dependent kinases CDK4 and 
CDK6 [143], bypassing then the normal checkpoints. In particular, the degradation of pRb causes, 
through a positive feedback mechanism, the increase of intracellular protein p16INK4a and leads to 
deregulated tumor cell proliferation [144,145]. These alterations have a dramatical impact on the oral 
mucosa, driving its malignant transformation. Nevertheless, it is very intriguing to note that they 
involve the same genes commonly mutated in OSCC due to the classical risk factors (alcohol and 
tobacco use). Several host epigenetic changes have been ascribed to HPV virus. The HPV appears to 
increase the de novo methyltransferase, DNMT3b protein; although no HPV protein has been identified 
as the culprit for this increase in DNMT3b, a recent study has now shown that HPV E7-protein increases 
DNA methyltransferase enzymatic activity by directly interacting with DNMT1. E7 protein has also 
been described to bind HDACs and Nurd ATP-dependent remodeling complex. Moreover, E6 protein 
binds and inhibits p300/CBP HAT [146–149]. 
The existence of a different clinical course among OSCCs arisen in HR-HPV+ and HPV− patients, 
confirm the hypothesis that epimutations and genetic mutations may have different consequences  
on the biological behavior of tumors, even if they tend to occur in a combined manner in most of 
human malignancies. 
8. Considerations 
Unlike genetic alterations, epigenetic changes are potentially reversible, and this feature makes 
them attractive targets for therapeutic intervention. Recent progresses in the knowledge of epigenetics 
of cancer have allowed the development of several inhibitors of DNA methiltransferase (DNMT), such 
as 5-azacitidine and decitabine, and histone deacetylase, successfully used in the treatment of several 
malignancies of the hematopoietic system, lung and even HNC [150–153]. The US NIH repository for 
clinical trials reports some trials involving epigenetic-based drugs in head and neck cancer treatment: 
Azacitidine and Cisplatin have been tested in combined chemotherapy in advanced, recurrent and 
metastatic squamous cell carcinoma of head and neck but no data are available to date about the 
outcome of the study  [154]. DNA methylation has been demonstrated to concur in the silencing of 
chemoresistance related genes; demethylating agents could improve the sensitivity of cancer cells to 
anticancer drugs [155]. The use of epigenetic inhibitors in association with traditional anticancer 
therapeutic agents looks very promising as a tool to improve the chemosensitivity of non-responsive Int. J. Mol. Sci. 2012, 13                 
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cancers [156]. A peculiar clinical benefit in OSCC, might be expected, for example, from the synergistic 
effect of epigenetic silencing of RASSF1 and radiotherapy to minimize radioresistance in OSCC [51]. 
Unfortunately, to date most of these therapeutic agents have shown some drawbacks, being toxic in vitro 
and in vivo. Nevertheless, the chance to counteract epigenetically-driven alterations in cancer cells opens 
an exciting scenario for its possible future fall-out on OSCC patients’ care. 
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